Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gudrun Piringer
Observed names:
G. Piringer,
GUDRUN PIRINGER,
Piringer, Gudrun
Institutions:
Johannes Kepler University of Linz,
Kepler Universitätsklinikum,
Austrian Breast & Colorectal Cancer Study Group
Observed institutions:
Johannes Kepler University of Linz,
Maastricht University Medical Centre,
Maastricht University,
Kepler Universitätsklinikum,
Arbeitsgemeinschaft medikamentöse Tumortherapie,
Klinikum Wels-Grieskirchen,
Austrian Breast & Colorectal Cancer Study Group
show all 7
ORCID:
0000-0002-2123-2148
Observed ORCID:
0000-0002-2123-2148
OpenAlex ID:
A5022833165
Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis
2020
·
Holger Rumpold
, Dora Niedersüß-Beke
, et al.
·
BMC Cancer
·
133
PDF
Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study
2015
·
Beate Mayrbäurl
, Johannes M. Giesinger
, et al.
·
Supportive Care in Cancer
·
57
Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment
2023
·
Bernhard Doleschal
, Hossein Taghizadeh
, et al.
·
Scientific Reports
·
30
PDF
Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry
2020
·
Florian Huemer
, Lukas Weiss
, et al.
·
Journal of Clinical Medicine
·
29
PDF
A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
2020
·
Matthias Unseld
, Jelena Belic
, et al.
·
International Journal of Cancer
·
25
PDF
Pretreatment Evaluation of Microcirculation by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Survival in Primary Rectal Cancer Patients
2014
·
Alexander Friedrich DeVries
, Gudrun Piringer
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
25
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
2018
·
Florian Huemer
, Josef Thaler
, et al.
·
BMC Cancer
·
23
PDF
Prognostic value of metastatic pattern in colorectal cancer: a multicenter retrospective analysis in a real-life cohort
2020
·
H. Rumpold
, P. Kirchweger
, et al.
·
Acta Oncologica
·
19
PDF
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence – A Phase II Study
2017
·
WOLFGANG EISTERER
, GUDRUN PIRINGER
, et al.
·
Anticancer Research
·
15
PDF
Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity
2024
·
I.-A. Mavroeidi
, J. Burghofer
, et al.
·
ESMO Open
·
14
PDF
A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients
2017
·
on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
, Gudrun Piringer
, et al.
·
Supportive Care in Cancer
·
13
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
2022
·
Verena Schlintl
, Florian Huemer
, et al.
·
BMC Cancer
·
12
PDF
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group
2022
·
Michael Leisch
, Michael Pfeilstöcker
, et al.
·
Cancers
·
11
PDF
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1
2020
·
Sonja Heibl
, Veronika Buxhofer‐Ausch
, et al.
·
Hematological Oncology
·
11
Influence of a Structured Exercise Training on Patients Reported Quality of Life in Colorectal Cancer Patients After Adjuvant Chemotherapy: A Pilot Study
2020
·
Gudrun Piringer
, Bernhard Holzner
, et al.
·
Integrative Cancer Therapies
·
11
PDF
Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review
2023
·
Gudrun Piringer
, Jörn Decker
, et al.
·
Frontiers in Oncology
·
10
PDF
Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
2020
·
Florian Huemer
, Gudrun Piringer
, et al.
·
Cancers
·
10
PDF
Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
2022
·
Ralf-Dieter Hofheinz
, Sandro Anchisi
, et al.
·
Cancers
·
8
PDF
REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancer
2020
·
Gudrun Piringer
, Laurenz Vormittag
, et al.
·
Wiener klinische Wochenschrift
·
6
Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer – a retrospective analysis
2024
·
Gudrun Piringer
, Florian Ponholzer
, et al.
·
Frontiers in Oncology
·
5
Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age
2021
·
Dora Niedersüß-Beke
, Manuel Orlinger
, et al.
·
Cancers
·
5
PDF
Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial
2024
·
Yawen Dong
, Jonas Santol
, et al.
·
Cancers
·
4
PDF
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study
2023
·
Gudrun Piringer
, Josef Thaler
, et al.
·
Journal of Geriatric Oncology
·
4
Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry
2021
·
Lisa Pleyer
, Michael Pfeilstocker
, et al.
·
Blood
·
3
Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group
2019
·
Lisa Pleyer
, Michael Pfeilstocker
, et al.
·
Blood
·
3
Show more works
View as search
Works count:
56
Citation count:
504
H-index:
12
I10-index:
17
Year
Topic
Type